Catalyst Pharma launches Agamree in the USA

14 March 2024

US biopharma company Catalyst Pharmaceuticals (Nasdaq: CPRX) has announced the US commercial launch of Agamree (vamorolone) oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients aged two years and older.

The drug is licensed from Swiss drugmaker Santhera Pharmaceuticals (SIX: SANN), which gained approval from the US Food and Drug Administration (FDA) on October 26, 2023, and is now available by prescription and dispensed throughout the USA via a specialty pharmacy network.

"Today, we proudly announced the US commercial availability of Agamree, an innovative alternative steroid treatment for Duchenne muscular dystrophy. This significant milestone offers hope for improved quality of life for individuals living with this devastating rare disease, as current steroid treatment options often involve a significant side effect burden," stated Richard Daly, chief executive of Catalyst.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK